Profund Advisors LLC decreased its stake in Edwards Lifesciences Corp (NYSE:EW) by 23.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,675 shares of the medical research company’s stock after selling 2,304 shares during the quarter. Profund Advisors LLC’s holdings in Edwards Lifesciences were worth $865,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in EW. Bank of New York Mellon Corp boosted its position in shares of Edwards Lifesciences by 45.7% in the 4th quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after purchasing an additional 2,377,444 shares during the period. Atlantic Trust Group LLC boosted its position in Edwards Lifesciences by 734.7% during the 3rd quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock worth $100,018,000 after acquiring an additional 805,370 shares during the period. Alliancebernstein L.P. boosted its position in Edwards Lifesciences by 12.1% during the 4th quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock worth $705,539,000 after acquiring an additional 675,216 shares during the period. Janus Henderson Group PLC boosted its position in Edwards Lifesciences by 1,135.0% during the 3rd quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock worth $67,739,000 after acquiring an additional 569,525 shares during the period. Finally, Champlain Investment Partners LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $56,393,000. Institutional investors and hedge funds own 82.90% of the company’s stock.
Shares of Edwards Lifesciences stock traded down $3.40 during trading on Friday, hitting $137.51. 1,776,081 shares of the stock traded hands, compared to its average volume of 1,296,813. The firm has a market cap of $29,594.44, a price-to-earnings ratio of 36.19, a P/E/G ratio of 2.07 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41. Edwards Lifesciences Corp has a twelve month low of $92.90 and a twelve month high of $143.22.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The business had revenue of $888.50 million during the quarter, compared to analyst estimates of $868.45 million. During the same period in the previous year, the company earned $0.75 EPS. The firm’s revenue was up 15.7% on a year-over-year basis. equities research analysts predict that Edwards Lifesciences Corp will post 4.52 earnings per share for the current year.
A number of equities research analysts have commented on EW shares. BMO Capital Markets restated a “buy” rating and set a $137.00 price objective on shares of Edwards Lifesciences in a research report on Friday, December 8th. Cowen set a $135.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Sunday, December 10th. JPMorgan Chase lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Evercore ISI started coverage on Edwards Lifesciences in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $140.00 price objective for the company. Finally, Barclays upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $144.16.
In related news, CFO Scott B. Ullem sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 28th. The stock was sold at an average price of $137.33, for a total value of $3,433,250.00. Following the transaction, the chief financial officer now directly owns 35,968 shares of the company’s stock, valued at approximately $4,939,485.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $126.69, for a total value of $4,155,432.00. Following the completion of the transaction, the chief executive officer now directly owns 74,131 shares in the company, valued at $9,391,656.39. The disclosure for this sale can be found here. Insiders sold a total of 191,603 shares of company stock worth $25,589,717 over the last three months. 2.13% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Profund Advisors LLC Lowers Stake in Edwards Lifesciences Corp (EW)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/edwards-lifesciences-corp-ew-holdings-reduced-by-profund-advisors-llc.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.